Education
About Us
Working with TipRanks
Follow Us
Synlogic (SYBX)
OTHER OTC:SYBX
SYBX Stock Chart & Stats
$1.22
$0.02(1.41%)
At close: 4:00 PM EST
$1.22
$0.02(1.41%)
Day’s Range― - ―
52-Week Range$0.54 - $1.96
Previous CloseN/A
Volume234.00
Average Volume (3M)41.08K
Market Cap
$7.02M
Enterprise Value-$7.53M
Total Cash (Recent Filing)$14.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,698,919
10 Day Avg. Volume24,108
30 Day Avg. Volume41,078
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.16
Enterprise Value/Market Cap-1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.88
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Engineered Microbial Medicines PlatformSynlogic’s platform approach of programming microbes to perform targeted biochemical functions is a durable strategic asset: it enables multiple pipeline programs across metabolic and immunology indications, supports technology reuse across assets, and creates a differentiated scientific moat that can produce long‑term program optionality and licensing or partnership opportunities.
Conservative Leverage (zero Debt)Having no reported debt in recent years materially lowers refinancing and interest burden risk, giving management flexibility to fund R&D through equity or partnerships rather than fixed obligations. This conservatism preserves downside protection and increases strategic optionality when executing longer clinical development timelines.
Sharply Reduced Cash Burn In 2025A meaningful reduction in operating cash outflows reflects durable cost discipline and restructuring that cut operating burn. Lower ongoing cash requirements extend runway, reduce near‑term financing pressure, and improve odds management can advance key clinical milestones or secure non‑dilutive partnerships over the coming months.
Bears Say
Nasdaq Delisting And Move To OTCDelisting to the OTC materially reduces liquidity, visibility, and access to many institutional investors, increasing the cost and difficulty of raising capital. For a clinical‑stage biotech dependent on funding for trials, constrained capital access raises execution and dilution risk over the medium term.
Minimal And Volatile RevenueIrregular and essentially negligible revenues mean the company cannot rely on product cash flows to fund development. This structural absence of recurring revenue increases dependency on capital markets or partners, making program continuity sensitive to financing cycles and heightening dilution risk over the coming months.
Shrinking Equity Base And Persistent LossesSubstantial erosion of shareholders’ equity from cumulative losses reduces the company’s financial buffer and limits flexibility to absorb setbacks. Combined with ongoing negative operating results, the weaker equity base increases the likelihood of future fundraising, potential dilution, or alternative strategic transactions that may constrain long‑term autonomy.
Synlogic News
SYBX FAQ
What was Synlogic’s price range in the past 12 months?
Synlogic lowest stock price was $0.54 and its highest was $1.96 in the past 12 months.
What is Synlogic’s market cap?
Synlogic’s market cap is $7.02M.
When is Synlogic’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Synlogic’s earnings last quarter?
Currently, no data Available
Is Synlogic overvalued?
According to Wall Street analysts Synlogic’s price is currently Overvalued.
Does Synlogic pay dividends?
Synlogic does not currently pay dividends.
What is Synlogic’s EPS estimate?
Synlogic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synlogic have?
Synlogic has 11,698,919 shares outstanding.
What happened to Synlogic’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synlogic?
Currently, no hedge funds are holding shares in SYBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Technical Analysis
Lisata Therapeutics
―
Aptevo Therapeutics
―
SeaStar Medical Holding
―
Cingulate Inc
―
Allarity Therapeutics
―
Ownership Overview
0.37% Insiders
2.08% Mutual Funds
53.67% Other Institutional Investors
43.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---